Published Date: 14 Mar 2023
As the COVID-19 pandemic spreads, access to and delivery of health services has been disrupted like never before. How has it affected the treatment of prostate cancer?
Read Full NewsWalter Kernan, MD, senior research scientist at Yale University, discussed the latest primary stroke prevention guidelines and their focus on lifelong brain health and risk factor management.
Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.
FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma
Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma
IgA Nephropathy Prediction Model Aids 5-Year Survival Estimation
Increased Physical Activity Linked to Reduced Mortality In Peritoneal Dialysis
GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM
1.
A Lot Can Be Said About You by Including Yourself in Photos.
2.
Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?
3.
Providing essential cancer care to rural communities
4.
Many Americans unaware of links between HPV and cancers, poll reveals
5.
Patients face high out-of-pocket costs after incident cancer diagnosis
1.
Unveiling the Hidden Dangers of Hand Cancer: How to Protect Yourself
2.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
3.
Clinical Analysis of Prostate Cancer
4.
Understanding Fibrosarcoma: What You Need to Know
5.
Hematologic Toxicity of CDK4/6 Inhibitors in Breast Cancer: Meta-Analysis and Safety Data
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Navigating the Complexities of Ph Negative ALL - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation